Searching…
See Important Safety Information, including Boxed Warning. How AUSTEDO XR® (deutetrabenazine) extended-release tablets may help.
See Prescribing Information, including Boxed Warning. Find information for healthcare professionals about once-daily AUSTEDO XR.
Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Da...
PARSIPPANY, N.J., and TEL AVIV, Israel – – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world...
Quiver AI Summary Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with tardive dyskinesia (TD). ...
Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (extended-release) tablets led to meaningful improvements for adults living with tardive dyskinesia...
AUSTEDO® XR (deutetrabenazine) extended-release tablets is the first medication approved to treat both tardive dyskinesia and Huntington's disease chorea. See safety info including Boxed Warning.
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary ...
Tardive dyskinesia (TD) emerges as a complex movement disorder often linked to prolonged neuroleptic or antipsychotic medication use. While newer antipsychotics like aripiprazole offer reduced risk, managing TD requir...
